Pfizer Inc. plans to expand production at its facility in Kalamazoo, Michigan. The $750 million project is expected to create 300 jobs.

The 400,000-square-foot MAP production facility is a global supplier of sterile injectable, liquid, and semi-solid medicines, as well as active pharmaceutical ingredients, producing more than 144 products.

“At Pfizer, we continue to invest in our manufacturing infrastructure, building a more resilient supply chain so patients have the medicines and vaccines they need,” said Mike McDermott, Chief Global Supply Officer, Executive Vice President, Pfizer. “This latest investment in our Kalamazoo site will help us advance some of the most innovative manufacturing technologies in sterile injectable production and distribution, while increasing access to these vital medicines. The innovations we put into place in response to the pandemic are now part of our everyday ways of working. We are proud to be a leader in U.S. manufacturing and proud of the impact we have on patients and people around the world.”

The MAP facility advances sterile manufacturing technology by placing products into distinct modules. MAP phase 2 will incorporate technologically advanced aseptic manufacturing equipment, systems, and design, including multiple self-contained modular manufacturing lines. Proposed products in MAP 2 will utilize new mRNA technology and ultra-low temperature storage.

“Pfizer’s continued investment in Michigan highlights the state’s leadership in life sciences and medical device manufacturing and our commitment to growing high-wage tech jobs to strengthen economic opportunity for Michiganders,” noted MEDC CEO and Michigan Strategic Fund President and Chair Quentin Messer Jr. “We’re thrilled to be celebrating Pfizer’s latest commitment in Michigan, which marks its second in 2022, as they create good-paying jobs for our friends and neighbors here in Portage, in nearby Kalamazoo, and all throughout the Southwest Michigan region. Congratulations to the team at Pfizer. We cannot wait to see and support your continued success in 2022 and beyond.”